 |
Dr Andree Bates, Managing Director of Eularis, has written this important guide for all pharmaceutical industry sales and marketing directors.
Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? 3rd Edition is NOW available to purchase. Once we have received payment the report is provided to you in e-format as a PDF file. Buy online for immediate access now from this web site - or simply contact us directly by phone or email.
This web site is managed by NetworkPharma Ltd, who act as distributors for this Pharmaceutical Industry Sales Force Effectiveness report. All enquiries should be directed to Peter Llewellyn at:
NetworkPharma Ltd
Magdalen Centre
The Oxford Science Park
Oxford, OX4 4GA
United Kingdom
T: +44 (0) 1865 784390
E: peter@networkpharma.com
Registration 4392836
VAT 787 5676 55
|
|
 |
 |
Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? - 3rd Edition
Sales force represents the largest spend in sales and marketing and yet, study after study show that the returns gained from this spend is not particularly strong. Dr Andree Bates uses market data and case studies as evidence to argue the case.
Publication Date: June 2011
Pages: 59
ISBN: 9780980182705
 |
downloadable pdf(3.23MB)
Price:
£497.00
|
|
|
| For more details see the product information below or alternatively download the sample pages here. |
|
Publication Overview
OVERVIEW
With the ever increasing pressure to ensure maximum return on investment, sales force effectiveness (SFE) is becoming a high priority area in the global pharmaceutical industry. Sales force represents the largest spend in sales and marketing and yet study after study shows that the returns gained from this spend is not particularly strong and one recent IMS report found that pharma sales force effectiveness declined by 23% in the recent period of 2004 to 2005. Better metrics must be used to measure both the effectiveness and financial impact of SFE for this very significant budget.
The startling discovery that this comprehensive report uncovers is that the very metrics currently being used to assess sales force effectiveness are in fact themselves aiding its decline. Traditional pharmaceutical organizations are rigorously tracking and managing sales activity, but still falling short. Data emerging from the research concludes that current metrics are more focused on efficiencies than effectiveness - and do so to their own detriment.
This report dissects current SFE metrics and their limitation for the pharmaceutical industry in the United States, Europe and Japan. The report then discusses appropriate metrics to solve these problems and goes on to demonstrate implementation methods and issues.
Sales force effectiveness is a difficult concept to measure, but doing so can push pharmaceutical companies past today’s hurdles and into increased productivity and sales.
ABOUT THE AUTHOR
Dr Andrée Bates is the Managing Director of Eularis, a company that applies sophisticated analytical processes to quantify the sales impact of specific marketing programs for pharmaceutical brands. These analyses determine the financial return for individual sales and marketing activities as well as the optimal synergistic combination of activities (and budgets) to have maximum market share growth. Eularis offers brands and their agencies the bottom line facts: what messages, what activities (and what budgets) - in what combination - will provide what market share for your brand.
Andrée’s career has encompassed academic, clinical and pharmaceutical positions internationally. She has gained wide recognition within the Healthcare Industry internationally for ROI and marketing effectiveness measures in pharmaceutical marketing. She is the author of many publications on this topic in peer-reviewed journals. In addition, Andrée has lectured on e-detailing ROI in the Pharmaceutical MBA program at INSEAD Business School and on marketing ROI at the Center for Pharmaceutical Marketing Studies, Erivan K. Haub School of Business, St. Joseph’s University, Philadelphia.
CONTENTS
SECTION 1: Background - The Scale of the Sales Force Effectiveness Problem
SECTION 2: Assessment - Current Metrics Used and their Contribution to the Problem
a. Sales Force Size and Share of Voice
b. Sales Calls Per Day
c. What’s Missing
d. Future Measures
SECTION 3: The Problem With Sales Tools
SECTION 4: Changing the Focus
a. Customer Focus
i. Targeting
United States
Europe
ii. Relationships
iii. Call Quality
b. Message Focus
c. Continuous Monitoring
SECTION 5: Problems Specific to Europe with Sales Force Effectiveness
a. Western Europe
b. Central and Eastern Europe
SECTION 6: The Japanese Market: Sales Force Effectiveness Issues
SECTION 7: The Right Metrics to Solve the Problems
a. Efficiency versus Effectiveness
b. Targeting
c. Effectiveness Measurement: Moving Beyond ‘Recall’ and ‘Intent to Prescribe’
d. Sales Force Optimisation
SECTION 8: Implementation Issues
a. Productivity
b. Action Plan
c. Emotional Buy In
d. Where does ‘e’ fit in: The Role of eDetailing
e. CRM and other Technologies
SECTION 9: Results Analysis
a. Case Studies
SECTION 10: Ongoing Monitoring
SECTION 11: The Future?
|
[BACK TO TOP]
|
Contents lists for this report
|
[BACK TO TOP]
|
|
|
|
|
 |
|
|
|
|
 |
If you have any questions at all about
ordering this report, or if you would like to ask about alternative methods of payment or multiple-use licenses, please don't hesitate to contact Peter Llewellyn directly, at NetworkPharma Ltd:
T: +44 1865 784390
E: peter@networkpharma.com
|
|
|
